Please assess the completion status of the following clinical trial:

Trial Title: Tanezumab in Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Osteoarthritis of the knee according to ACR criteria with a Kellgren-Lawrence x-ray grade of 2.~* Unwilling or unable to take non-opiate pain medications, for whom non-opiate pain medications have not provided adequate pain relief or are candidates for knee injections arthroplasty or replace surgery.~* Pain level and function levels as required by the protocol at Screening and Baseline.~* Willing to discontinue pain medications (acetaminophen will be permitted up to a certain level) before and during the study.~* Must agree to the contraceptive requirements of the protocol if applicable.~* Must agree to the treatment plan, scheduled visits, and procedures of the protocol.~Exclusion Criteria:~* Pregnancy or intent to become pregnant during the study~* BMI greater than 39~* other severe pain, significant cardiac, neurological or psychological conditions, or above the protocol limits for laboratory and blood pressure results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Tanezumab 10 mg (Type: EXPERIMENTAL): None
- Tanezumab 5 mg (Type: EXPERIMENTAL): None
- Tanezumab 2.5 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).